HL23

HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC) . HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib (HY-10201) and is more potent than Sorafenib+Vorinostat (HY-10221) [1].

Product Specifications

CAS Number

[1448355-15-4]

UNSPSC

12352005

Target

HDAC

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/hl23.html

Purity

99.64

Solubility

10 mM in DMSO

Smiles

CN([C@@]1([H])CC2=CC=C(OC)C(OC3=CC=C(C[C@]4([H])N(C)CC5)C=C3)=C2)CCC6=C1C(OC7=C(OC)C=C5C4=C7)=C(OC(C8=CC=CC=C8)=O)C(OC)=C6

Molecular Formula

C44H44N2O7

Molecular Weight

712.83

References & Citations

[1]Lu Y, et al. Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma. J Adv Res. 2023 Sep;51:181-196.. .